Trial Profile

A Phase 2a Study to Evaluate the Effects of DaxibotulinumtoxinA for Injection on the Treatment of Dynamic Forehead Lines and Glabellar Lines

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daxibotulinumtoxin A (Primary)
Indications Glabellar lines
Focus Therapeutic Use
Sponsors Revance Therapeutics

Most Recent Events

21 May 2024 Status changed from not yet recruiting to recruiting.
04 Nov 2019 Status changed from recruiting to active, no longer recruiting, according to a Revance Therapeutics media release.
08 May 2019 According to a Revance Therapeutics media release, the company expects to complete enrollment in this trial in the summer of 2019 and top-line results are expected in 1H 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com